Acambis on hold by Jefferies

Jefferies & Co., Inc. analyst Robin Campbell rated Acambis plc at hold. While the CDC award is good news, it raises questions as to the requisition framework for Project BioShield, according to the analyst. Delays suggest a situation in flux. Second-quarter results are worked into Jefferies' model, resulting in downgraded forecasts. Shares of the Cambridge, England-based pharmaceutical company were down 2.00p, or 1.33%, at 148.00p. (London: ACM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.